By: Jared Kaltwasser
The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.
Jared Kaltwasser is a healthcare and business writer whose work has appeared in various publications, including AJMC - The American Journal of Managed Care, Contagion_Live, and Managed Healthcare Executive. With a focus on healthcare topics, Jared covers a wide range of subjects, from disease and treatment advancements to healthcare management and cost-effectiveness.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .